Journal of Korean Association of Cancer prevention 2003; 8(2): 63-72
Published online June 30, 2003
© Korean Society of Cancer Prevention
Su Jung Park1, Ju Youn Park1*, Kwang Yong Shim3, Yun-Bong Kim4, Seong Ho Kim4, Yong Hae Kim4 and Soo Kie Kim1,2
Echinomycin, typical DNA minor groove binder had comparable efficacy compared to 5-FU in phase II trial for colon cancer treatment. To improve echinomycin's drawback, we synthesized YK-2000 series (echinomycin analogues). Echinomycin and YK-2000 enabled to induce the apoptosis on HT-29 colorectal cancer cell line. Apoptosis in HT-29 cell triggered by echinomycin and YK-2000 were proven through DNA laddering, PARP (poly-(ADP-ribose) polymerase) cleavage and flow cytometric analysis. Such an apoptotic pattern displayed by YK-2000 was quite different from that of echinomycin. Next, to explore signaling pathway of echinomycin and YK-2000, we examined phosphorylation of extracellular signal-regulated kinase1/2 (ERK1/2), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) and p38 MAP kinase. However, it is not clearly that the mechanism of cancer cell death induced by echinomycin and YK-2000. Here, we report that one of major apoptotic signaling pathway induced by echinomycin and YK-2000 may be MAP kinase pathway in HT-29 human colon cancer cells.
Keywords: Echinomycin, YK-2000, Apoptosis, MAP kinase, PARP
Eung-Ryoung Lee, Geun-Ho Kang, Yong-Jin Kang, Woo-Yeul Kim, Hye-Yeon Choi, Bong-Woo Kim, Hyo-Soon Jeong and Ssang-Goo Cho
Cancer prevention research 2007; 12(3): 163-173Muhammad Haroon, Sun Chul Kang
J Cancer Prev 2024; 29(3): 69-87 https://doi.org/10.15430/JCP.24.013Jaeho Han, Donghwa Kim, Hyen Joo Park, Hee-Juhn Park, Sang Kook Lee
J Cancer Prev 2023; 28(4): 201-211 https://doi.org/10.15430/JCP.2023.28.4.201